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ABSTRACT
CD147 AS A POTENTIAL THERAPEUTIC TARGET IN GLIOBLASTOMA
TREATMENT
By
Beau Adams

Glioblastoma (GBM) tumors are the most common and lethal form of cancer in
the central nervous system (CNS). GBM tumors appear to contain a mixture of different
cell types, which makes them difficult to treat. GBM cells exhibit altered morphology
from normal cells on several different levels, which highlights different pathways to
potentially target for therapeutic treatments. The human surface glycoprotein CD147,
also known as basigin, is expressed at significantly higher levels in GBMs compared to
non-neoplastic brain tissue. Furthermore, levels of CD147 expression correlate with brain
tumor progression and show the highest expression in GBM. Here, we suppressed tumor
cell growth using anti-CD147 monoclonal antibodies. An apoptosis/necrosis assay
suggests that GBM cells treated with anti-CD147 monoclonal antibodies were not
experiencing a form of induced cell death. Rather, our cell proliferation assay results
suggest that anti-CD147 monoclonal antibody treated cells had significantly deceased cell
proliferation when compared with control cells. Together, these results show that CD147
is a potential therapeutic target for GBM treatment.
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INTRODUCTION

Glioblastoma (GBM) is the most common and lethal form of primary cancer in
the central nervous system (CNS). Glioblastoma is a type of tumor that develops from
glial cells, called astrocytes, which function to support nerve cells1. Glioblastomas are
highly malignant due to their fast growth rates and the extensive blood vessel networks
that form near them2. During development of the tumor, GBMs appear to contain a
mixture of specific differentiated cell types such as oligodendrocytes and ependymal
cells. As a result, some GBM cells may respond to specific therapies while others may
not respond at all, making GBMs extremely difficult to treat. Despite advances in cancer
therapy such as immunotherapy, the prognosis for GBM patients remains poor. Standard
GBM treatments include partial removal, chemotherapy, and radiation3. Chemotherapy
involves the use of drugs intended to kill cancer cells by stopping growth and
reproduction. Radiation involves the use of high-energy waves to damage tumor cell
DNA, which halts cell division and eventually destroys them. Unfortunately, these
treatments are only beneficial for a short period of time and can have negative effects
upon the surrounding normal tissues. The survival rate for GBM patients one-year post
diagnosis is 33% while the survival rate after five years is 4.5%4. Many research
laboratories across the world are working to find a potential therapeutic target for GBM
to increase the survival rates and improve the treatments of this deadly disease.
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The growth and spread of a tumor (called metastasis) involves several steps,
including increased cell proliferation, changes in cell motility leading to invasion of
surrounding tissues, and the formation of new blood vessels (angiogenesis). The process
of angiogenesis ensures that metabolically active tissues, including cancer, are never
more than a few hundred micrometers away from capillaries5. Angiogenesis is stimulated
when vascular endothelial growth factor (VEGF) binds to tyrosine kinase receptors
(VEGF-Rs), which then leads to activation of several downstream pathways that regulate
angiogenesis. Capillaries are crucial for the process of nutrient/metabolite exchange and
provide tissues with a consistent oxygen supply to metabolize substrates that are needed
for energy6. This is important because cancer cells require this nutrient/metabolite
exchange in order to survive7. Anti-angiogenic therapies designed to prevent the growth
of new blood capillaries are used to combat several diseases, including cancer. These
‘angiogenesis inhibitors’ generally block the activation of VEGF receptors. The drugs
bind to either VEGF and/or VEGF-Rs, blocking receptor binding and subsequent
activation of downstream signaling8. Angiogenic inhibitors have shown promise in GBM
patients but unfortunately exhibit a high percentage of relapse, which calls for a larger
understanding of the mechanisms involved in tumor growth.
Rapidly proliferating cells can become resistant to the body’s normal defenses,
and some can evade endogenous cell death programs designed to prevent unwanted cell
growth9. Normally, cytotoxic and helper T cells inhibit cancer development through
production of cytokines and cytotoxins9. However, things such as chronic inflammation
can override these effects to promote cancer. When acute immune responses fail to
eliminate cancer cells, unresolved chronic inflammation promotes tumor cell growth and
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angiogenesis9. The human immune system is normally capable of eliminating cancer cells
that express mutated proteins (neoantigens), which are molecules encoded by tumorspecific mutated genes. However, increases in cancer cell proliferation also generates
cells that can evade immune responses, allowing some cancer cells to escape immune
system elimination9. Increased cell proliferation leads to the production of immune
suppressive cytokines, either by tumor cells or normal cells present in the tumor
microenvironment. These cytokines, such as TNF-alpha, IL-1, and IL-6 assist in the
evasion of immune surveillance by weakening T cell response9. For example, TNF-α
promotes cell survival via TNFR1 through its activation of specific transcription factors,
which cause downstream activation of the PI3K/Akt/MDM2 pathway (expanded upon in
the following pages)10. IL-1 induces expression of metastatic genes involved in tumor
progression such as VEGF, TNF-α, and other interleukins11. IL-6 protects tumor cells
from oxidative stress, DNA damage, and apoptosis by facilitating signaling pathways
involved in cell survival, which also includes the PI3K/Akt/MDM2 pathway12.
Another dangerous property of GBMs is their ability to invade nearby tissues,
leading to another obstacle of treatment. A good way to summarize this process is the
invasion-metastasis cascade13. This cascade occurs when primary tumor cells invade the
surrounding extracellular matrix (ECM) followed by invasion of the lumina of blood
vessels, where tumor cells can be transported through the vasculature. Finally, the tumor
cells can move into the parenchyma of distant tissues and then reinitiate their
proliferation. These invasive properties contribute to tumor survival and induce
molecular changes that maximize metastasis13. An understanding of this process is
critical for the development of new techniques to diagnose and treat GBM. The first step
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in the metastatic process is local invasion, which refers to cancer cells from the primary
tumor entering adjacent tissue. In order to invade the tissue, cancer cells must penetrate
the basement membrane (BM), a special type of extracellular matrix that separates
epithelial and stromal components10. From here, these cancer cells must invade lymphatic
and blood vessels (intravasation). Intravasation occurs when molecular changes allow
these cancer cells to cross endothelial cell barriers that make up blood vessel walls.
Examples of molecules promoting intravasation include transforming growth factor-β
(TGFβ), epidermal growth factor (EGF), and colony stimulating factor-1 (CSF-1)14. Once
cancer cells have intravasated into blood vessels, they become circulating tumor cells
(CTCs) and must survive to successfully metastasize. In the absence of any anchorage,
normal cells in circulation would usually go through anoikis – a type of apoptosis due to
loss of anchorage. Cancer cells are able to overcome anoikis due to specific molecules
such as tyrosine kinase receptor B (TrkB) that assists in suppression of the immune
response15. In a study by Douma et al., it was shown that TrkB activates the
phosphatidylinositol-3-OH kinase/protein kinase B pathway which induced formation of
cellular aggregates that survived in suspension – therefore overcoming anoikis15.
Eventually, the CTCs arrest at specific sites and begin to invade the walls of surrounding
vessels, making direct contact with tissue parenchyma. This process is known as
extravasation13. In a recent study by Gao et al., CTCs were identified in 77% of
glioblastoma patients16. CTCs are thought to be one of the main reasons for tumor
recurrence in many forms of cancer, including GBM17.
An example of a molecule that may be involved in all of these tumor-promoting
properties is the human surface glycoprotein basigin. The basigin gene is located at p13.3
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on chromosome 19 and consists of ten exons spanning 12 kb18. Basigin is a member of
the immunoglobulin family of cell surface proteins and is expressed as four different
isoforms. The transmembrane domain is almost completely conserved across all species,
while the cytoplasmic domain is only moderately conserved19. The largest isoform,
known as basigin-1, has three immunoglobulin domains within the extracellular domain
and is expressed specifically in the retina18. Basigin-2, also commonly called CD147, is
the isoform expressed at relatively high levels in many cell types and possesses two
immunoglobulin domains within the extracellular domain. The core protein portion of
basigin-2 is 28 kDa18, and during processing in the cell, it becomes heavily glycosylated
on three asparagine residues resulting in an increase in its weight to 43-66 kDa20. For the
purpose of this thesis, basigin-2 will be referred to as CD147 unless specified otherwise.
A study by Jia et al. looked closer at CD147 glycosylation, specifically its interaction
with other molecules. Since CD147 associates with caveolin-1 (Cav-1), the authors
looked into its effect on glycosylation. Using an RNA interference (RNAi) model, it was
shown that downregulation of Cav-1 suppressed the conversion of CD147 into its higher
glycosylated form, exhibiting the importance of the CD147/Cav-1 association21.
Additionally, it was originally thought that CD147 was only able to exhibit stimulatory
activity if glycosylated. However, a study by Belton et al. demonstrated that activation is
not dependent upon glycosylation of the CD147 ligand22.
CD147 is normally involved in a number of biological processes including
embryonic development, sensory regulation, and immunological responses18. While
CD147 expression is elevated in rapidly proliferating tumor cells, it is also found in
leukocytes, macrophages, epithelial cells (blood vessel walls), red blood cells, and the
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endometrium; but not in normal glia23-24. A study by Geng et al. found that CD147
promoted M1 macrophage activity in the lungs, which induced the differentiation of cells
in lung fibrosis25. Another study by Coste et al. examined the function of CD147 in red
blood cells. In this study, anti-CD147 monoclonal antibody (mAb) treatment disrupted
the circulation of red blood cells, leading to cellular trapping in the spleen24. In a study of
CD147 deficient mice, the majority of embryos died during implantation. The surviving
mutant mice were born underdeveloped and died well before adulthood26. In normal
mice, CD147 was highly expressed in the embryo proper, endometrium, and trophoblast
cells. The early deaths of knockout-CD147 mice suggest its important role in
embryogenesis and reproduction22. CD147 has also been found to play an important role
in the sensory nervous system, as the survival and function of photoreceptors in the retina
is dependent upon CD147 through its affiliation with monocarboxylate transporters
(MCTs) in the plasma membrane of retinal cells27. In the immune system, recent studies
have shown that CD147 affects T-cell activation as well as T-cell development28. In
CD147-knockout mice, thymus development was arrested in early stages28. Furthermore,
T cell proliferation was significantly increased when CD147 was knocked down using
siRNA-mediated gene silencing29. Through confocal microscopy, it was found that
CD147 is recruited to the immunological synapse during T cell activation30. The
immunological synapse is the space between the antigen-presenting cell and a
lymphocyte. Using a CD147-EGFP (enhanced green fluorescent protein), Ruiz et al.
observed that CD147 translocated from the plasma membrane to the immunological
synapse upon T cell activation31.
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In cancer cells, CD147 expression levels are significantly higher than in normal
tissue. Furthermore, the levels of CD147 expression correlate directly with tumor severity
and progression in gliomas and show the highest expression in GBM32. In fact, CD147
expression is upregulated in nearly every type of cancer, including breast, cervical, colon,
lung, and melanoma among others33. In GBM, CD147 promotes tumor growth, inhibits
cell death, and enhances the invasiveness of tumor cells34. Interactions with many
specific proteins are a key part of CD147 function. CD147 acts as an extracellular matrix
metalloproteinase (MMP) inducer by stimulating the release of MMPs from fibroblast
cells. MMP induction is initiated when a soluble basigin ligand binds to a CD147 cell
surface receptor, stimulating the ERK 1/2 signaling pathway which induces expression of
MMPs22. Matrix metalloproteinases can then degrade the extracellular matrix and
therefore assist with tumor invasiveness, angiogenesis, and increased cell survival.
CD147 also contributes to angiogenesis independently of MMPs by increasing vascular
endothelial growth factor (VEGF), which assists in blood vessel formation as discussed
earlier35. In a study by Tang et al., VEGF expression was induced in a CD147 dose
dependent manner. Furthermore, VEGF expression was inhibited by suppressing CD147
expression in tumor cells by using an anti-CD147 mAb31. CD147 has been shown to act
as a coreceptor for VEGFR2 in both tumor and endothelial cells. Since CD147 is
overexpressed in most cancers, this causes enhanced activation of the VEGFR2 which
leads to increased angiogenesis for tumor cells36.
CD147 also interacts with cell surface transmembrane glycoproteins called
integrins, and the association of CD147 with integrins is important for cell adhesion,
migration, metastasis, and cell signaling37. In CD147 mutant mice, the disruption of this
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interaction lead to cellular dysfunction such as abnormal distribution of organelles,
including the mitochondria, nuclei, and endoplasmic reticulum37-38. In multiple sclerosis,
CD147 regulates alpha-4 integrin expression on T cells. A flow cytometry assay showed
that T cells treated with an anti-CD147 mAb had reduced alpha-4 integrin expression on
the cell surface39. While examining the mechanism by which this occurs, Agrawal et al.
showed that anti-CD147 mAb treatment inhibited the nuclear factor kB (NFkB) pathway.
To test this, the authors examined IκBα protein levels 2 hours post anti-CD147 mAb
treatment39. IκBα is a protein that functions to inhibit NFkB by interfering with its cell
signaling. Western blot analysis demonstrated that when treated with the anti-CD147
mAb, IκBα levels decreased in the cells39.
Another important protein group that CD147 associates with are cyclophilins,
which bind extracellularly and transmit their signals. Cyclophilin A is a peptidylprolyl
isomerase normally expressed inside cells but is secreted in response to immunological
stimuli such as inflammation and antigen presentation. Secreted cyclophilins promote
chemotactic activity for neutrophils, eosinophils, and T cells18. Chemotaxis occurs when
a cell moves in response to a chemical stimulus. CD147 has been shown to act as a
receptor for cyclophilin A and mediate its chemotactic activity towards target cells. This
CD147-cyclophilin interaction is important for the inflammatory process of several
diseases, including GBM40. A recent study by Jin et al. demonstrated that cyclophilin A is
secreted by cells in response to oxidative stress41. Therapeutic agents that have reduced
CD147 expression exhibited a significant anti-inflammatory response, suggesting that the
CD147/cyclophilin interaction could be a potential target for anti-inflammatory therapy.
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CD147 inhibition through an anti-CD147 mAb reduced inflammation by more than 50%
in mouse models with lung inflammation, asthma, and rheumatoid arthritis40.
CD147 is also indirectly involved in the transport of metabolites such as lactate
and pyruvate across the plasma membrane. Monocarboxylate transporters (MCTs) play a
central role in this transport, and CD147 forms a complex on the cell surface with these
transporters42. Walters et al. used immunofluorescence analysis to demonstrate that
CD147 specifically interacts with both MCT1 and MCT4 in cancer cells43. MCTs are
involved in the regulation of glycolytic metabolism, which is crucial for the expansion of
neoplastic tissue44. Under low oxygen (hypoxic) conditions, glucose is catabolized to
lactate through glycolysis to form ATP because the mitochondria can’t use oxidative
phosphorylation to create ATP without oxygen. Cancer cells can also produce lactate
under aerobic conditions – switching from glycolysis and oxidative phosphorylation to
strictly cytosolic glycolysis45. This phenomenon is called the ‘Warburg effect’ thanks to
its leading contributor, Otto Warburg (figure 1). Lactate, the end product of anaerobic
glycolysis, causes acidosis in cells and must be pumped out for cancer cells to remain
functional42. In a study by Baba et al., blocking expression of the CD147/MCT complex
using an anti-CD147 mAb was shown to decrease the number of melanoma and colon
cancer cells in vitro through an accumulation of lactate and a decreased pH.
Immunofluorescence analysis showed that after mAb treatment, MCT was being
internalized into the cell, suggesting internalization of the CD147/MCT complex. This is
problematic because the CD147/MCT complex carries out its function on the cell surface.
This response was specific for cancer cells, and not for normal fibroblasts42. In the study,
it is important to note the authors did not detect apoptosis in the anti-CD147 mAb treated
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cells, and assumed the decreased cell numbers were caused by necrosis. This is a major
assumption because other factors could be causing this, such as an interruption of the cell
cycle leading to decreased proliferation.
Eukaryotic cells have two main mechanisms of cell death – apoptosis and
necrosis. Apoptosis is a process of enzyme-mediated, programmed cell death whereas
necrosis is described as accidental cell death due to environmental stress. The
morphology of cells undergoing apoptosis is characterized by cytoplasmic condensation
and cellular fragmentation into membrane-bound fragments46. Specific proteases called
caspases are integral to the apoptotic response. Caspase activation is involved in the
production of pro-inflammatory cytokines such as IL-147. Caspase proteolysis of
substrates is responsible for the morphological changes in apoptotic cells. Another
caspase-dependent process used for apoptosis detection is phosphatidylserine (PS)
exposure. In a paper by Martin et al., it was shown that inhibition of specific caspases
lead to inhibition of PS externalization.48. Molecules called flippases are responsible for
keeping PS in the inner leaflet of the plasma membrane, while scramblases are
responsible for translocating PS to the outer leaflet49. When cells begin apoptosis, PS
moves from the inner leaflet to the outer leaflet of the plasma membrane, which exposes
it to be detected46. The morphology of cells that experience necrotic cell death is
significantly different from apoptosis. Necrotic cell death is accompanied by cell
swelling, organelle distension, degradation of nuclear DNA, and plasma membrane
autophagy31. Necrosis is considered to be passive because it requires minimal energy and
isn’t regulated by any homeostatic mechanism. Necrosis occurs due to several
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environmental factors such as nutrient deprivation, reactive oxygen species, toxin
exposure, and severe changes in physiological conditions50.
Aside from cell death, inhibition of signaling pathways can also lead to a
decreased number of cells, this time without actually killing them. In a 2014 paper by
Huang et al., it was shown that CD147 significantly suppresses p53 protein levels51. P53
is a tumor suppressor gene that regulates cellular metabolic stress responses. P53 activity
is very low in normal cells, but is increased in response to cellular stress such as DNA
damage and oncogene activation52. The primary regulator of p53 is mouse double minute
2 homolog (MDM2), which functions to inhibit p53 transcriptional activation. MDM2
does this by acting as a ubiquitin ligase, which induces proteasome degradation to
decrease p53 protein levels52. Many studies have shown that p53 inhibits the expression
of glucose transporters GLUT1 and GLUT4, which are both crucial for energy
production51. P53 is downstream of the PI3K/Akt/MDM2 signal transduction pathway,
which is critical in cellular functions such as proliferation, glucose metabolism, and
angiogenesis (figure 2). Specific growth factors lead to activation of this pathway and one
of these key regulators is epidermal growth factor (EGF) and its receptor EGFR. EGFR
lays directly upstream of the PI3K/Akt/MDM2 pathway and its activation leads to
activation of the pathway53. EGFR is a receptor tyrosine kinase (RTK) that is upregulated
in several types of cancers including breast cancer, pancreatic cancer, and GBM53. To
become activated, RTKs generally require ligand binding that eventually leads to
phosphorylation of the receptor. Interestingly enough, in cancer, RTKs can become
phosphorylated in the absence of a ligand. Overexpression or mutations of RTKs can lead
to clustering of receptors, causing them to homodimerize and become phosphorylated
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without a ligand54. Interestingly enough, EGFR variant 3 (EGFRvIII), which is a ligandindependent receptor, is overexpressed in GBM55. EGFR is known for its role in cell
proliferation and inhibition of apoptosis, which is why it is labeled as a proto-oncogene.
A proto-oncogene is a normal gene that has potential to become mutated and eventually
cause cancer. In a paper by Grass et al, it was demonstrated that CD147 forms a complex
with EGFR in lipid-raft membrane domains56. To test this, a proximity ligation assay
(PLA) that examines the association of specific proteins was conducted. The assay
demonstrated that there is close association between CD147 and EGFR inside membrane
fractions of cancer cells56. Given that CD147 is also directly upstream of the
PI3K/Akt/MDM2 signaling pathway, it was hypothesized by Huang et al. that CD147activated Akt may lead to the degradation of p53. Upon further analysis, it was found that
phosphorylation of Akt and MDM2 was significantly decreased when CD147 was either
knocked down or knocked out, all while p53 levels increased. These results suggest that
CD147 may activate the PI3K/Akt/MDM2 pathway to inhibit p53 by promoting its
degradation51. Furthermore, the study demonstrated an inverse correlation between lactic
acidosis and PI3K/Akt activity. Huang et al. found that Akt activity was reduced by a
MCT1 specific siRNA or a MCT1 inhibitor, while it was significantly increased in MCT1
overexpressing cells51. Taken together, this data suggests that the CD147/MCT complex
along with EGFR activity play a role in activating the PI3K/Akt/MDM2 pathway. To
conclude, inhibiting CD147 may subsequently inhibit the PI3K/Akt/MDM2 pathway,
leading to increased p53 expression and its tumor suppressing properties.
In the human body, cells are either surrounded by the extracellular matrix or are
in direct contact with other cells. However, most in vitro biology techniques culture cells
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in a two-dimensional (2D) monolayer on plastic, which isn’t representative of a cells
natural microenvironment57. In an attempt to mimic the body as accurately as possible,
three-dimensional (3D) cell culturing techniques have recently been developed. In the
thesis presented here, an improved cell culturing technique was developed to culture
multi-cellular 3D spheroids using ultra-low attachment 96-well plates. Three-dimensional
growth of cells is now regarded as a more reliable model in comparison to single
adherent cells when conducting cell culture assays. Spheroids possess several similar
features of tumors such as cell interactions, response, and resistance58. Improvements of
several other physiological aspects have also been highlighted using 3D cell culture, such
as – cell viability, morphology, proliferation, differentiation, invasion, angiogenesis, and
cell function59. The 3D spheroid model more closely imitates in vivo cells, with the
expectation that it will give the most accurate and reliable results. In the work discussed
below, we used a 3D cell culture system and anti-CD147 mAbs to test whether CD147
could be targeted for anti-tumor therapy.

13

AIMS AND GOALS

Glioblastoma (GBM) is the most common and lethal form of primary cancer in
the central nervous system. While normal glial cells do not express CD147, the
transmembrane glycoprotein is highly overexpressed in GBM. CD147 contributes to
critical tumor promoting properties, which eventually lead to increased tumor cell
survival. This presents an important target for a potential therapeutic treatment. CD147
forms a complex with monocarboxylate transporters (MCTs) on the cell surface, which
serves as an important regulator of intracellular homeostasis. Activation of this complex
may lead to activation of the PI3K/Akt/MDM2 pathway, which subsequently inhibits
p53, an important tumor suppressing protein. A 2008 paper by Baba et al. showed that
blocking formation of the CD147/MCT complex using an anti-CD147 mAb decreased
the number of melanoma and colon cancer cells through an accumulation of lactate and a
decreased pH42. This decreased cell number was exhibited in cancer cells, but not in
normal fibroblasts42.
Our hypothesis was that treating U87MG GBM cells with anti-CD147 mAbs
would suppress tumor cell growth in a multi-cellular tumor spheroid model. To test this
hypothesis, U87MG GBM multi-cellular tumor spheroids were grown in 96-well ultralow attachment round bottom plates, and treated with anti-CD147 mAbs. During mAb
treatment, spheroids were measured every 24 hours and compared to controls. The
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possible mechanism by which the mAbs suppressed cell growth was tested to determine
if the effects were a result of cell death or cellular proliferation.
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METHODS AND MATERIALS

Cell Culture
U87MG adherent cells (ATCC) were cultured in Eagle’s Modified Essential
Medium (EMEM; Corning, Manassas, VA) with 10% Fetal Bovine Serum (FBS; Atlanta
Biological, Atlanta, GA). The media was supplemented with 1% Penicillin-StreptomycinAmphotericin B (PSA; Lonza, Walkersville, MD) to prevent bacterial and fungal
contamination. Under laminar flow, frozen aliquots of cells were resuspended in 8.5 ml
of culture media and then transferred to 75cm2 tissue treated flasks. Each flask was
incubated at 37ºC and 5% CO2 until cells became nearly confluent, where cells were then
either passaged 1:3, harvested for replating or for spheroid assays.
Spheroid Antibody Assay
Once nearly confluent, cells were removed from the flask with trypsin-versene
(Lonza) and pelleted at 1000 rpm for 5 minutes. Pelleted cells were resuspended in 10 ml
culture medium, and the live cells were counted using a hemacytometer (Hausser
Scientific, Horsham, PA) following trypan blue solution staining of the cells (VWR Life
Science AMRESCO, Radnor, PA). 96-well round bottom ultra low attachment plates
(Corning) were used for the growth of spheroids. Cells were plated at 500 cells/well in
100 μl of culture media. Immediately after cell plating, an additional 100 μl of either
antibody-treated media, or normal culture media was added to each well. Three different
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anti-CD147 monoclonal antibodies (mAbs) were used throughout the duration of these
assays – Ab666 (Abcam, Cambridge, MA), MEM-M6/1 (Genetex, Irvine, CA), and P2C2
(Dr. Robert Belton, University of Illinois). Antibody treatment consisted of two different
concentrations for each mAb – 2 μg/ml, and 10 μg/ml. Seven wells were used for each
treatment condition. Spheroid cultures in the 96-well plate were placed into incubation
and analyzed for growth at 24-hour time points for 7 days. Spheroids were measured
using an ocular micrometer attached to a Microscoptics IV900 series microscope. A
Canon EOS Rebel T6 camera attached to the microscope was used to photograph each
spheroid at 24-hour time points.
Apoptosis/Necrosis Detection Assay (Abcam)
24-well tissue treated plates (Corning) were used for cell culture. 12mm poly-d
lysine coated coverslips (Corning) were placed at the bottom of each well to be used for
fluorescent microscopy upon assay completion. Cells were plated at 20,000 cells/well in
500ml of culture media. Immediately after cell plating, an additional 500ml of either
antibody-treated media, or normal culture media was added to each well. Anti-CD147
mAb ab666 was used at a concentration of 10 μg/ml for each treatment well. Cells were
then placed into incubation and grown for 4 days. After day 4, prior to beginning the
apoptosis/necrosis detection kit, positive control cells were treated with 1 μm
staurosporine for 3.5 hours to induce cell death. All cells were then washed 2 times with
500 μl assay buffer, by carefully pipetting the buffer up and down. Next, cells were
resuspended in 600 μl assay buffer and treated with 6 μl 100X apopxin deep red
indicator, 3 μl 200X nuclear green, and 3 μl 200X cytocalcein 450 in order to measure
the presence of apoptotic or necrotic events. Cells were then incubated at room
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temperature for 45 minutes. After incubation, cells were washed with 500 μl assay buffer
then resuspended in 500 μl assay buffer. Finally, cells were imaged using cellSens
software and an Olympus DP72 fluorescent microscope.
CellQuanti-Blue Proliferation Assay (BioAssay Systems)
Living cells actively reduce the CellQuanti-Blue solution and convert it into a
highly fluorescent product. The measured fluorescent activity directly correlates with a
cells metabolic activity, which provides a relatively easy way to measure cell
proliferation. For this assay, cells were plated at 5,000 cells/well in 50 μl of culture
media. Black 96-well clear bottom plates (Corning) were used for cell culture.
Immediately after cell plating, an additional 50 μl of either antibody-treated media, or
normal culture media was added to each well. Anti-CD147 mAb ab666 was used at a
concentration of 10 μg/ml for each treatment well. Cells were then placed into incubation
and grown for 4 days. After day 4, CellQuanti-Blue reagent was equilibrated to room
temp then added to each well at a volume of 10 μl. Cells were then incubated at room
temperature for 2 hours and subsequently analyzed on a Modulus microplate multimode
reader (Turner Biosystems, Sunnyvale, CA) using a 530 excitation/590 emission filter.
Statistical Analysis
Spheroid size was averaged for each culture condition and plotted for daily
change in growth in Microsoft excel. Data from each antibody concentration was
analyzed against the control in a paired t-test for each day using GraphPad. Data with a P
value <0.05 was considered significant. Data with a P value <0.01 was considered highly
significant. Data with a P value <0.001 was considered extremely significant. For
apoptosis/necrosis detection, a cell count was done for each stain to determine percent
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change between control and treated samples. Data from the CellQuanti-Blue proliferation
assay was calculated as percent change in cell number of treated cells compared with
controls. Data with a P value <0.05 was considered significant. Data with a P value <0.01
was considered highly significant. Data with a P value <0.001 was considered the most
significant.
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RESULTS

Spheroid Growth
Because the literature indicates that CD147 interference/knockdown leads to
decreased tumor cell survival, it was hypothesized that anti-CD147 mAbs would inhibit
CD147 function and therefore suppress spheroid growth. Prior to setting up the spheroid
antibody assay, it was first demonstrated that U87MG cells could form spheroids.
Initially, two different types of spheroid plates were used. Plates treated with polyHEMA and plates treated with agarose were both initially tested. Both substances were
used because of their relatively low prices and their ability to produce hydrophobic
surfaces in the culture dish, which favor spheroid growth. Spheroids were able to form in
both plates, but the bottom of the plates contained so much amorphous material that
images were distorted, making spheroid measurements impossible. To correct this, ultralow attachment plates were purchased from Corning and used for the remainder of the
study. U87MG cells formed spheroids in these low-attachment plates and allowed for
clear images.
Spheroid Antibody Assay
Initially, to assure spheroids would grow in the presence of mAbs, 500 U87MG
cells were plated along with anti-CD147 mAb ab666 at a concentration of 10 μg/ml.
After incubating overnight, spheroids formed and therefore allowed for the spheroid
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antibody assay to begin. The spheroid assay was done in three different trials, with seven
different spheroids grown in each each row for every trial (figure 3). In trial 1, five rows
were tested. For row A, U87MG cells were plated at 500 cells/well and then treated with
standard culture media for a final volume of 200 μl. Cells were grown for 7 days and
measured at 24-hour time points (figures 4-6). For rows B and C, U87MG cells were
plated at 500 cells/well and then treated with anti-CD147 mAb ab666 at concentrations of
2 μg/ml and 10 μg/ml, respectively. Spheroids were grown for 7 days and measured at
24-hour time points (figures 7-9). For rows D and E, U87MG cells were plated at 500
cells/well and then treated with anti-CD147 mAb P2C2 at concentrations of 2 μg/ml and
10 μg/ml, respectively. Spheroids were grown for 7 days and measured at 24-hour time
points (figures 10-12). For trials 2 and 3, a 2nd clone of anti-CD147 mAb MEM-M6/1
was acquired and used throughout the assays. Trials 2 and 3 now had 7 rows in
comparison to 5 rows in trial 1. Rows A-E remained the same as trial 1, while 2 new
culture conditions were added. For rows F and G, U87MG cells were plated at 500
cells/well and then treated with anti-CD147 mAb MEM-M6/1 at concentrations of 2
μg/ml and 10 μg/ml, respectively. Spheroids were grown for 7 days and measured at 24hour time points (figures 13-15).
Data for all 3 mabs was averaged and graphed using Microsoft Excel (figures 1618). Anti-CD147 mab ab666 significantly suppressed spheroid growth on all days after
day 1 at a concentration of 10 μg/ml. Growth was suppressed up to 24 percent of the
control. Anti-CD147 mab P2C2 significantly suppressed spheroid growth on all days
after day 1 at a concentration of 10 μg/ml. Growth was suppressed up to 11 percent of the
control. Anti-CD147 mab MEM-M6/1 significantly suppressed spheroid growth on all
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days after day 1 at a concentration of 10 μg/ml. Growth was suppressed up to 32 percent
of the control. Taken together, it can be said with confidence that CD147 interference
through the use of anti-CD147 mAbs significantly suppressed cell growth.
Apoptosis/Necrosis Assay
In order to determine the possible mechanism(s) for anti-CD147 mAb inhibition
of spheroid growth, a cell death assay was performed. Instead of 96-well plates, 24-well
plates were used and seeded at a higher density. Well 1 was used as the positive control.
U87MG cells were plated at 20,000 cells and treated wih standard culture media. After
growing for 4 days, cells were treated with 1 μm staurosporine for 3.5 hours to induce
cell death and then imaged on a flurouescence microscope (figures 19-22). Figure 19
shows live cells, stained with CytoCalcein Violet 450. Figure 20 shows the same culture
stained for apoptotic cells using the Apopxin Deep Red Indicator. Figure 21 shows
necrotic cells, stained with Nuclear Green DSC1. Figure 22 shows the overlay image of
the 3 stains. 3.5 hours of 1 μm staurosporine successfully induced cell death in the
U87MG cells, demonstrating positive staining for both apoptosis and necrosis. Well 2
was used as the negative control. U87MG cells were plated at 20,000 cells and treated
with standard culture media. Cells were grown for 4 days and then imaged on a
fluroecence microscope (figures 23-26). Figure 23 shows live cells, stained with
CytoCalcein 450. Figures 24 and 25 were stained for apoptosis and necrosis respectively.
The results are negative for both stains, meaning that the negative control cells did not
undergo either mechanism of cell death as a result of the culturing procedures used.
Figure 26 shows the overlay image for all 3 stains. Well 3 was the anti-CD147 mAb
treated cells. U87MG cells were plated at 20,000 cells and treated with anti-CD147 mAb
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ab666 at a concentration of 10 μg/ml. Cells were grown for 4 days and then imaged on a
fluorescence microscope (figures 27-39). Figure 27 shows live cells, stained with
CytoCalcein 450. Figures 28 and 29 were stained for apoptosis and necrosis respectively.
The results were negative for both stains, meaning that the anti-CD147 mAb treated cells
are not experiencing any mechanism of cell death. Figure 30 is the overlay image of all 3
stains. All 3 conditions were graphed using Microsoft Excel (figure 31) and expressed as
a percent change between control and treated samples. The positive control cells showed
significant amounts of both mechanisms of cell death while the negative control and mAb
treated cells showed no form of cell death.
CellQuanti-Blue Proliferation Assay
The CellQuanti-Blue proliferation assay followed a similar protocol as previous
assays. U87MG cells were plated into a 96-well plate at 5,000 cells/well and treated with
anti-CD147 mAb ab666 at a concentration of 10 μg/ml, or left untreated. After 4 days of
growth, cells were treated with 10 μl of Cell-Quanti Blue reagent and incubated for 1
hour. Fluorescent intensity was then measured for each well on a fluorescent microplate
reader using the 530 excitation/590 emission filter. Graphpad was used to create the
graph (figure 32) of cell proliferation. Data was expressed as a percent change between
treated and control samples. Ab666 mAb treatment significantly decreased cell
proliferation when compared to untreated control cells. A paired t test presented a value
of 0.005, confirming significance of the data.
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Figure 1: The Warburg effect. In the presence of oxygen, normal cells produce their
energy through oxidative phosphorylation. In the absence of oxygen, cells will produce
energy through anaerobic glycolysis. Cancer cells produce the majority of their energy,
even in the presence of oxygen, though aerobic glycolysis followed by lactic acid
fermentation. This is called the Warburg effect. Taken from “Understanding the Warburg
effect: the metabolic requirements of cell proliferation” by Heiden et al., 2009, Science,
Vol. 324, pg. 1029-1033. Used with permission.
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Figure 2: PI3K/Akt/MDM2 pathway. CD147 stimulates the PI3K/Akt/MDM2
pathway. Activation of this pathway leads to the inhibition of p53, a tumor suppressor
genes involved in the cell cycle. CD147 inhibition leads to inhibition of the
PI3K/Akt/MDM2 pathway, and therefore removes the p53 blockade, allowing it to
perform its proper function. Taken from “CD147 promotes reprogramming of glucose
metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling
pathway” by Huang et al., 2014, Journal of Hepatology, Vol. 4, pg. 859-866. Used with
permission.
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Spheroid Antibody Assay Experimental Design
Untreated Control
Ab666 2 ug/ml
Ab666 10 ug/ml
P2C2 2 ug/ml
P2C2 10 ug/ml
MEM-M6/1 2 ug/ml
MEM-M6/1 10 ug/ml

* MEM-M6/1 not used in trial 1

Figure 3: Spheroid antibody assay experimental design. Row A contains the untreated
control. Row B contains ab666 at a concentration of 2 ug/ml. Row C contains ab666 at a
concentration of 10 ug/ml. Row D contains P2C2 at a concentration of 2 ug/ml. Row E
contains P2C2 at a concentration of 10 ug/ml. Row F contains MEM-M6/1 at a
concentration of 2 ug/ml. Row G contains MEM-M6/1 at a concentration of 10 ug/ml.
MEM-M6/1 was only used in trials 2 and 3.
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Figure 4: Untreated U87MG cells – day 0. U87MG cells were plated at 500 cells/well.
Picture was taken at 4x magnification immediately after cell plating on day 0.
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Figure 5: Untreated spheroid – day 3. Control well. Cells were plated at 500 cells/well.
Picture was taken at 4x magnification after 72 hours of growth on day 3. Spheroid is 300
micrometers. Measurements were taken using an ocular micrometer and converted using
the 4x magnification scale.
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Figure 6: Untreated spheroid – day 6. Control well. Cells were plated at 500 cells per
well. Picture was taken at 4x magnification after 144 hours of growth on day 6. Spheroid
is 475 micrometers. Measurements were taken using an ocular micrometer and converted
using the 4x magnification scale.
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Figure 7: U87MG cells treated with mAb ab666 at 10 μg/ml – day 0. Cells were
plated at 500 cells per well and treated with anti-CD147 mAb ab666 at a concentration of
10 μg/ml. Picture was taken at 4x magnification immediately after cell plating on day 0.
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Figure 8: Spheroid treated with mAb ab666 at 10 μg/ml – day 3. Cells were plated at
500 cells per well and treated with anti-CD147 mAb ab666 at a concentration of 10
μg/ml. Picture was taken at 4x magnification after 72 hours of growth on day 3. Spheroid
is 225 micrometers. Measurements were taken using an ocular micrometer and converted
using the 4x magnification scale.
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Figure 9: Spheroid treated with mAb ab666 at 10 μg/ml – day 6. Cells were plated at
500 cells per well and treated with anti-CD147 mAb ab666 at a concentration of 10
μg/ml. Picture was taken at 4x magnification after 144 hours of growth on day 6.
Spheroid is 375 micrometers. Measurements were taken using an ocular micrometer and
converted using the 4x magnification scale.
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Figure 10: U87MG cells treated with mAb P2C2 at 10 μg/ml – day 0. Cells were
plated at 500 cells per well and treated with anti-CD147 mAb P2C2 at a concentration of
10 μg/ml. Picture was taken at 4x magnification immediately after cell plating on day 0.
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Figure 11: Spheroid treated with mAb P2C2 at 10 μg/ml – day 3. Cells were plated at
500 cells per well and treated with anti-CD147 mAb P2C2 at a concentration of 10
μg/ml. Picture was taken at 4x magnification after 72 hours of growth on day 3. Spheroid
is 275 micrometers. Measurements were taken using an ocular micrometer and converted
using the 4x magnification scale.
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Figure 12: Spheroid treated with mAb P2C2 at 10 μg/ml – day 6. Cells were plated at
500 cells per well and treated with anti-CD147 mAb P2C2 at a concentration of 10
μg/ml. Picture was taken at 4x magnification after 144 hours of growth on day 6.
Spheroid is 425 micrometers. Measurements were taken using an ocular micrometer and
converted using the 4x magnification scale.
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Figure 13: U87MG cells treated with mAb MEM-M6/1 at 10 μg/ml – day 0. Cells
were plated at 500 cells per well and treated with anti-CD147 mAb MEM-M6/1 at a
concentration of 10 μg/ml. Picture was taken at 4x magnification immediately after cell
plating on day 0.
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Figure 14: Spheroid treated with mAb MEM-M6/1 at 10 μg/ml – day 3. Cells were
plated at 500 cells per well and treated with anti-CD147 mAb MEM-M6/1 at a
concentration of 10 μg/ml. Picture was taken at 4x magnification after 72 hours of growth
on day 3. Spheroid is 200 micrometers. Measurements were taken using an ocular
micrometer and converted using the 4x magnification scale.
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Figure 15: Spheroid treated with mAb MEM-M6/1 at 10 μg/ml – day 6. Cells were
plated at 500 cells per well and treated with anti-CD147 mAb MEM-M6/1 at a
concentration of 10 μg/ml. Picture was taken at 4x magnification after 144 hours of
growth on day 6. Spheroid is 325 micrometers. Measurements were taken using an ocular
micrometer and converted using the 4x magnification scale.
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Figure 16: Average change in spheroid diameter (Ab666). U87MG cells were treated
with either control culture media or anti-CD147 mAb ab666. 7 spheroids were grown for
each treatment condition. Antibodies were administered at concentrations of 2 μg/ml and
10 μg/ml. Cells were grown for a total of 7 days and analyzed at 24-hours time points.
Ab666 at a concentration of 10 μg/ml suppressed spheroid growth on all days after day 1.
Growth was suppressed up to 24 percent of the control. A paired t-test indicated that the
data from all time points was significant when compared to the control.
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Figure 17: Average change in spheroid diameter (P2C2). U87MG cells were treated
with either control culture media or anti-CD147 mAb P2C2. 7 spheroids were grown for
each treatment condition. Antibodies were administered at concentrations of 2 μg/ml and
10 μg/ml. Cells were grown for a total of 7 days and analyzed at 24-hours time points.
P2C2 at a concentration of 10 μg/ml suppressed spheroid growth on all days after day 1.
Growth was suppressed up to 11 percent of the control. A paired t-test indicated that the
data from all time points was significant when compared to the control.
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Figure 18: Average change in spheroid diameter (MEM-M6/1). U87MG cells were
treated with either control culture media or anti-CD147 mAb MEM-M6/1. 7 spheroids
were grown for each treatment condition. Antibodies were administered at concentrations
of 2 μg/ml and 10 μg/ml. Cells were grown for a total of 7 days and analyzed at 24-hours
time points. MEM-M6/1 at a concentration of 10 μg/ml suppressed spheroid growth on
all days after day 1. Growth was suppressed up to 32 percent of the control. A paired ttest indicated that the data from all time points was significant when compared to the
control.
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Figure 19: Positive control stained positive for live cells. U87MG cells were grown for
4 days then treated with 1 μm staurosporine in a 37(0), 5% CO2 incubator for 3.5 hours.
Image shows live cells (blue, stained with CytoCalcein Violet 450). Image was taken
with an Olympus DP72 fluorescence microscope through the violet channel. Data
indicates the positive control contained live cells beginning to cluster.
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Figure 20: Positive control stained positive for apoptosis. U87MG cells were grown
for 4 days then treated with 1 μm staurosporine in a 37(0), 5% CO2 incubator for 3.5
hours. Image shows apoptotic cells (red, stained with Apopxin Deep Red Indicator).
Image was taken with an Olympus DP72 fluorescence microscope through the Cy5
channel. Data indicates staurosporine treatment induced apoptosis on positive control
cells.
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Figure 21: Positive control stained positive for necrosis. U87MG cells were grown for
4 days then treated with 1 μm staurosporine in a 37(0), 5% CO2 incubator for 3.5 hours.
Image shows necrotic cells (green, stained with Nuclear Green DCS1). Image was taken
with an Olympus DP72 fluorescence microscope through the FITC channel. Data
indicates staurosporine treatment induced necrosis on positive control cells.
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Figure 22: Positive control overlay image. U87MG cells were grown for 4 days then
treated with 1 μm staurosporine in a 37(0), 5% CO2 incubator for 3.5 hours. Image shows
cells that are alive (blue, stained with CytoCalcein Violet 450), apoptotic cells (red,
stained with Apopxin Deep Red Indicator), and necrotic cells (green, stained with
Nuclear Green DCS1). Image shows cells beginning to go through both apoptosis and
necrosis due to staurosporine treatment. Overlay was produced from the same population
of cells. Image was taken with an Olympus DP72 fluorescence microscope through the
violet, Cy5, and FITC channel respectively.
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Figure 23: Negative control stained positive for live cells. Untreated U87MG cells
were grown in a 37(0), 5% CO2 incubator for 4 days. Image shows live cells (blue,
stained with CytoCalcein Violet 450). Image was taken with an Olympus DP72
fluorescence microscope through the violet channel. Data indicates that the negative
control contained living cells.
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Figure 24: Negative control stained negative for apoptosis. Untreated U87MG cells
were grown in a 37(0), 5% CO2 incubator for 4 days. Cells were stained for apoptosis
(red, Apopxin Deep Red Indicator). No apoptosis was detected. Image was taken with an
Olympus DP72 fluorescence microscope through the Cy5 channel.
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Figure 25: Negative control stained negative for necrosis. Untreated U87MG cells
were grown in a 37(0), 5% CO2 incubator for 4 days. Cells were stained for necrosis
(green, Nuclear Green DCS1). No necrosis was detected. Image was taken with an
Olympus DP72 fluorescence microscope through the FITC channel.
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Figure 26: Negative control overlay image. Untreated U87MG cells were grown in a
37(0), 5% CO2 incubator for 4 days. Cells were stained for live cells (blue, stained with
CytoCalcein Violet 450), apoptotic cells (red, stained with Apopxin Deep Red Indicator),
and necrotic cells (green, stained with Nuclear Green DCS1). Image shows only live
cells, indicating that the negative control cells are going through neither apoptosis nor
necrosis. Overlay was produced from the same population of cells. Image was taken with
an Olympus DP72 fluorescence microscope through the violet, Cy5, and FITC channel
respectively.
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Figure 27: Anti-CD147 mAb treated cells stained positive for live cells. U87MG cells
were treated with ab666 mAb (10 μg/ml) in a 37(0), 5% CO2 incubator for 4 days. Image
shows live cells (blue, stained with CytoCalcein Violet 450). Image was taken with an
Olympus DP72 fluorescence microscope through the violet channel.
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Figure 28: Anti-CD147 mAb treated cells stained negative for apoptosis. U87MG
cells were treated with ab666 mAb (10 μg/ml) in a 37(0), 5% CO2 incubator for 4 days.
Cells were stained for apoptosis (red, Apopxin Deep Red Indicator). No apoptosis was
detected. Image was taken with an Olympus DP72 fluorescence microscope through the
Cy5 channel.
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Figure 29: Anti-CD147 mAb treated cells stained negative for necrosis. U87MG cells
were treated with ab666 mAb (10 μg/ml) in a 37(0), 5% CO2 incubator for 4 days. Cells
were stained for necrosis (green, Nuclear Green DCS1). No necrosis was detected. Image
was taken with an Olympus DP72 fluorescence microscope through the FITC channel.
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Figure 30: Anti-CD147 mAb treated cells overlay image. U87MG cells were treated
with ab666 mAb (10 μg/ml) in a 37(0), 5% CO2 incubator for 4 days. Cells were stained
for live cells (blue, stained with CytoCalcein Violet 450), apoptotic cells (red, stained
with Apopxin Deep Red Indicator), and necrotic cells (green, stained with Nuclear Green
DCS1). Image shows only live cells, indicating that the antibody treatment caused neither
apoptosis nor necrosis. Overlay was produced from the same population of cells. Image
was taken with an Olympus DP72 fluorescence microscope through the violet, Cy5, and
FITC channel respectively.
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Figure 31: Anti-CD147 mAb treatment does not induce cell death. Analysis of
apoptosis and necrosis on U87MG cells after 4 days in the presence of ab666 mAb (10
μg/ml), staurosporine (1 μm), or no treatment. No cell death was observed in the negative
control nor the mAb treated cells. Data was expressed as percent change between control
and treated samples. Apoptosis and necrosis was only detected in the positive control
cells treated with 1 μm staurosporine.
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Figure 32. Anti-CD147 mAb treatment caused decreased cell proliferation. Analysis
of cell proliferation in U87MG cells after 4 days of ab666 mAb treatment (10 μg/ml), or
no treatment. Cell proliferation significantly decreased in the mAb treated cells. Data was
expressed as percent change between control and treated samples.
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DISCUSSION

While it has been shown that CD147 interference/knockdown suppresses cell
growth in adherent melanoma and colon cancer cells42, this would be a novel finding in
GBM multicellular tumor spheroids. In the present work, we have shown that anti-CD147
mAbs (ab666, MEM-M6/1, & P2C2) significantly suppress U87MG spheroid growth.
Previous studies have demonstrated that CD147 forms a complex with monocarboxlate
transporters on the cell surface, and it seems this interaction is crucial for tumor cell
survival42. Directly downstream of the CD147/MCT complex lies the PI3K/Akt/MDM2
pathway – an important system that controls the tumor suppressor gene p5351. P53
activity is increased in response to cellular stress such as DNA damage and oncogene
activation52. The primary regulator of p53 is MDM2, which functions to inhibit p53
transcriptional activation52. One specific study showed that phosphorylation of Akt and
MDM2 was significantly decreased when CD147 was either knocked down or knocked
out51. Additionally, p53 levels increased when CD147 was being inhibited51. This
highlights a direct correlation between CD147 and the PI3K/Akt/MDM2 pathway. The
study also highlighted an inverse correlation between lactic acidosis and PI3K/Akt
activity, showing that Akt activity was reduced by a MCT1 inhibitor51. Additionally, Akt
activity was significantly increased in MCT1 overexpressing cells. This highlights the
importance of the CD147/MCT complex in the function of the PI3K/Akt/MDM2
pathway. Specific growth factors are responsible for activation of the PI3K/Akt/MDM2
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pathway, and one molecule that lays directly upstream is EGFR, a receptor tyrosine
kinase. To become activated, RTKs generally require ligand binding that eventually leads
to phosphorylation of the receptor. However, in cancer, RTKs can become
phosphorylated in the absence of a ligand54. Overexpression or mutations of these
receptors can lead to clustering, causing them to homodimerize and become
phosphorylated. This autophosphorylation leads to constant activation of the pathway,
which can eventually lead to cancer. As mentioned previously, all of this data suggests
that the CD147/MCT complex along with EGFR activity play a role in activating the
PI3K/Akt/MDM2 pathway. We believe that interfering with CD147 function may
subsequently inhibit the PI3K/Akt/MDM2 pathway, leading to increased p53 expression
and its tumor suppressing properties.
While Baba et al. reported similar findings to ours in their 2008 paper; there are
key differences with our current work. Baba et al. reported that inhibiting expression of
the CD147/MCT complex using mAb ab666 decreased the number of melanoma and
colon cancer cells, but not normal fibroblasts42. While searching for the mechanism to
explain this finding, an apoptosis assay was done which resulted in negative data. It was
then assumed that since the hallmarks of apoptosis were not seen, the reason for
decreased cell numbers was necrotic cell death. This is a major assumption because other
factors could be causing this, such as an interruption of cellular metabolism leading to
decreased proliferation. We investigated this possibility by using multicellular spheroids.
Once cell culture conditions were optimized, multicellular tumor spheroids were grown
using U87MG cells and treated with the same mAb used by Baba et al., along with two
other anti-CD147 mAbs. As hypothesized, these anti-CD147 mAbs significantly

57

suppressed spheroid growth during the 7-day treatment. An interesting finding within
these results is that two of the mAbs (ab666 & MEM-M6-1) had more significant effects
on spheroid growth than the other (P2C2). In fact, the two mAbs that showed higher
significance are the same mAb clone produced by different manufacturers. According to
both manufacturers, this antibody clone recognizes and binds to an epitope in the Nterminal Ig domain (D1). This could be an important factor for the difference seen
between the effects of the different mAbs. The site at which an antibody binds, whether
extracellularly or intracellularly, could play a large role in mab effect.
In order to determine how these mAbs suppressed spheroid growth, a cell death
assay for both apoptosis and necrosis was used. Using the same culture conditions,
U87MG cells were grown in the presence of ab666 for four days. To test for these
mechanisms of cell death, positive control cells, negative control cells, and mAb treated
cells were stained with three different stains after the growth period was complete.
Positive control cells are used to represent the response being tested, whereas negative
control cells represent normal cells with no response. A live cell stain, an apoptosis stain,
and a necrosis stain were all used in combination to test for cell death in all three culture
conditions. The live stain (CytoCalcein Violet 450) works by entering the cytoplasm of
live cells, where specific esterases cleave an ester group from the stain, which yields the
fluorescent dye. Dead cells that have compromised cell membranes are not able to
complete this process. The apoptotic stain (Apopxin Deep Red) works by binding directly
to phosphatidylserine, which moves to the outside of the cell during apoptosis allowing
for easy detection which is observed as red fluorescent light. Phosphatidylserine on the
cell surface is a universal indicator of the early signs of apoptosis, and can be detected

58

before cell morphology changes drastically. The necrotic stain (Nuclear Green DCS1) is
a membrane impermeable dye that enters the nucleus of cells that have lost their
membrane integrity due to cellular damage and fluoresces as green light. As expected, the
positive control cells treated with staurosporine, which induces cell death, stained
positive for both apoptosis and necrosis. Again, as expected, the untreated negative
control cells were negative for both apoptosis and necrosis staining. Like Baba et al., our
mAb treated cells were negative for apoptosis staining. Our results differed, though,
when it came to necrotic cell death. The mAb treated cells were also negative for necrosis
staining, which raised the question of how these cells could be experiencing a decrease in
cell growth.
A literature review of tumor cell proliferation was performed to find a possible
clue to explain our results. We learned that the CD147/MCT complex lies directly
upstream of the PI3K/Akt/MDM2 pathway51. We also learned that EGFR lies directly
upstream of the pathway and acts as a functional regulator for PI3K/Akt/MDM2
activation53. Finally, it was learned that CD147 forms a complex with EGFR inside lipid
rafts of the plasma membrane, which could have serious implications in our study56.
CD147 and EGFR are both overexpressed in GBM, which leads to increased tumor cell
survival by promoting cancerous properties. Since EGFR acts as a regulator for the
PI3K/Akt/MDM2 pathway, its activation leads to activation of the pathway.
Overexpression of EGFR may cause receptor clustering and can eventually lead to
homodimerization and autophosphorylation of the receptor. This would activate the
pathway in the absence of a ligand, ultimately promoting cancer. The PI3K/Akt/MDM2
pathway is critical for cellular functions such as proliferation, glucose metabolism, and
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angiogenesis.
When functioning properly, p53 can inhibit the downstream effects of the
PI3K/Akt/MDM2 signaling pathway in tumor cells. Using the CellQuanti-Blue
proliferation assay, we analyzed the proliferation of mAb treated cells versus control
cells. After growing cells in both conditions for 4 days, cells were stained with
CellQuanti-Blue reagent and incubated for an hour. Following incubation, cells were
analyzed for total fluorescence, which represents proliferation. Overall, the mAb treated
cells had a decreased proliferation rate of nearly 40% when compared with the control.
Rather than cell death, these GBM cells treated with anti-CD147 mAbs appear to
experience a significant decrease in cell proliferation. Reviewing the literature gives a
molecular basis for these results. Interference of the CD147/MCT/EGFR complexes has
potential to cause serious problems for tumor cell survival. We believe that anti-CD147
mAb binding is causing internalization of these complexes, inhibiting their function and
leading to inhibition of the PI3K/Akt/MDM2 pathway. Since these complexes carry out
their functions on the cell surface, internalization into the cell would prevent them from
being able to function properly. Overall, the inhibition of this pathway would remove the
inhibition of tumor suppressor p53 and allow it to carry out its proper function –
suppressing tumor cells.
To further analyze the effects of our different mAbs, epitope mapping of each
antibody should be done to confirm exactly where each mAb is binding to its target
protein. Locating the exact binding site of an antibody provides crucial information when
developing a new therapeutic drug. Further analysis of the PI3K/Akt/MDM2 pathway
should also be completed to confirm the hypothesis of its downstream role in tumor cell
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proliferation. Following mAb treatment, cellular levels of EGFR, Akt and p53 could be
measured and compared to a control. Other techniques besides mAb treatment could also
be used to inhibit CD147 function, such as a true knockdown or knockout to analyze the
effects it may have on this pathway.
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CONCLUSION

In conclusion, we have demonstrated that anti-CD147 monoclonal antibodies
suppress the growth of U87MG multicellular tumor spheroids. Furthermore, we have
shown that when treated with these mAbs, U87MG cells are not undergoing apoptosis or
necrosis. We have also shown that cellular proliferation is significantly decreased post
antibody treatment, showing a decreased proliferation rate of nearly 40 percent when
compared with control cells. It is likely that these findings are a result of the
PI3K/Akt/MDM2 pathway being subsequently inhibited by CD147 interference, although
further analysis will be needed to confirm this hypothesis. For future GBM treatment, we
have came to two important conclusions; monoclonal antibodies can be used to target the
specific CD147 protein, and CD147 is a worthwhile therapeutic target for GBM.
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APPENDIX A

License to use Figure 1 from “Understanding the Warburg effect: the metabolic
requirements of cell proliferation” by Heiden et al. received from The American
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APPENDIX B

License to use Figure 2 from “CD147 promotes reprogramming of glucose metabolism
and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway”
by Huang et al. received from Elsevier Publishing.

69

